AOD-9604 in Cléon — Fat Loss Peptide Research Guide
AOD-9604 research guide for Cléon. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Unlike common nutraceuticals stocked in every health store, AOD-9604 is distributed via a global research peptide market that Cléon residents access almost entirely online. This matters because AOD-9604 quality differs enormously across the market — from analytically confirmed high-purity product to products with serious contamination — and the vendor controls every quality variable. A credible AOD-9604 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Cléon researcher needs before placing a first order.
Understanding AOD-9604 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Cléon comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
Assessing AOD-9604 vendors requires starting from the COA: access the batch-specific certificate before purchasing, not after. The HPLC chromatogram is the most important document in the COA: it should show a dominant main peak representing AOD-9604, with negligible secondary peaks representing impurities — purity should be 98% or higher. Red flags in AOD-9604 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. The lyophilised (freeze-dried) form of AOD-9604 is much more stable than liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations break down rapidly even under refrigeration.
Order AOD-9604 — ships to Cléon
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. The main safety concern arising from sourcing in AOD-9604 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. Researchers combining AOD-9604 with other compounds should check the research literature for any reported interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
